Existing users please login

Forgot Password

    Home / Markets / Industries / Health Care

    Tuesday, November 17, 2009

    Alkermes Begins Trials for ALKS 33

    | Respond to Editor | Print

     
    FOXBusiness
       

      Alkermes (ALKS) announced Tuesday it has begun phase 2 clinical trials of ALKS 33, a drug designed to treat alcohol dependence. The drug, which is known as an “opioid modulator” may also be used to treat nervous system disorders.

      Alkermes trials will look at the safety and effectiveness of ALKS 33 when given in multiple doses to 440 patients over the course of 12 weeks. Patients will receive the placebo and the drug at random. Patients have been asked to abstain from alcohol use while participating in the trial.

      The news of this trial comes after the company’s Monday announcement that that opioid dependence drug Vivitrol will be marketed in 2010 following a positive clinical trial.

      Fox Business Video


      Last 5 Stocks

      • Ticker
      • Company
      • Price
      • Change
       

      Personal Finance - Investing - Financial News - Business News - Stock Market Quotes & News - Small Business

      Advertise with us | Jobs at FOX Business Network | Internships at FBN

      Terms of use. Privacy Statement. For FOXBusiness.com technical issues write to foxbusinessonline@foxbusiness.com; for all other feedback, write to feedback@foxbusiness.com.

      Quotes delayed at least 15 minutes. Market Data provided by Interactive Data (Terms & Conditions). Powered and implemented by Interactive Data Managed Solutions. Company fundamental data provided by Morningstar. Earnings estimates data provided by Zacks. Mutual fund data provided by Lipper. Economic data provided by Econoday. Dow Jones & Company Terms & Conditions.

      This material may not be published, broadcast, rewritten, or redistributed. ©2010 FOX News Network, LLC. All rights reserved.